Last reviewed · How we verify
Sprains and Strains — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Qutenza | CAPSAICIN | Averitas | capsaicin | Transient receptor potential cation channel subfamily V member 1 | 2009-01-01 | |
| Salonpas | METHYL SALICYLATE | Hisamitsu Pharm Co | methyl salicylate | 2008-01-01 | ||
| Voltaren | DICLOFENAC | Hisamitsu Pharmaceutical Co., Inc | Nonsteroidal Anti-inflammatory Drug | Prostaglandin G/H synthase 2 | 1988-01-01 | |
| Arthrotec | Diclofenac Sodium | Pfizer | diclofenac | Acid-sensing ion channel 3 | 1988-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Sprains and Strains
- Averitas · 1 drug in Sprains and Strains
- Hisamitsu Pharm Co · 1 drug in Sprains and Strains
- Hisamitsu Pharmaceutical Co., Inc · 1 drug in Sprains and Strains
- Pfizer · 1 drug in Sprains and Strains
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Sprains and Strains:
- Sprains and Strains treatment updates — RSS
- Sprains and Strains treatment updates — Atom
- Sprains and Strains treatment updates — JSON
Cite this brief
Drug Landscape (2026). Sprains and Strains — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sprains-and-strains. Accessed 2026-06-10.
Related
- Sprains and Strains full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing